NY Times
JANUARY 12, 2021
In their first abortion case since Justice Amy Coney Barrett joined the court, the justices reinstated a requirement that women seeking medication abortions pick up a pill in person.
pharmaphorum
JANUARY 15, 2021
J&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the virus ahead of a phase 3 trial readout due later this month. The UK has caused controversy in recent weeks by tinkering with the dosing regimens for coronavirus vaccines from AstraZeneca and Pfizer/BioNTech, which are being rolled as part of the country’s mass vaccination programme.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
JANUARY 11, 2021
Partnership will aim to research and implement quantum computing in pharma R&D
Pharma Mirror
JANUARY 10, 2021
By Boris Goldstein, Co-Founder & Executive Chairman at Brain Scientific COVID-19 is known for its impacts on a patient’s respiratory system, but it has also been found to affect individuals in unique ways and with varying severity levels depending on their age, risk factors, and comorbidities. Several studies have recently shown that the development of neurological conditions and symptoms are prevalent in COVID patients.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
NY Times
JANUARY 11, 2021
Participants with the disease still declined, but much more slowly than those receiving a placebo, investigators say.
pharmaphorum
JANUARY 15, 2021
Pharma’s reputation is currently riding high as the industry comes together to tackle COVID-19, but GSK’s UK general manager Neale Belson says there is always more companies can do to build their culture and make sure employees and customers trust they are doing the right thing. When we spoke with Belson about the GSK’s response to COVID-19 , he pointed out how the pandemic has allowed him to get to know his colleagues even better than he anticipated.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Outsourcing Pharma
JANUARY 13, 2021
A leader from the anti-counterfeit solutions firm says that while packaging-level efforts may have an effect, on-dose technology is worth a closer look.
NY Times
JANUARY 15, 2021
One of the world’s largest inoculation programs is set to begin on Saturday, but experts have questioned the data behind one of the country’s two vaccines — and patients don’t get to pick their shot.
pharmaphorum
JANUARY 15, 2021
Women with newly-diagnosed advanced ovarian cancer have a new treatment option in England after NICE recommend interim funding for GlaxoSmithKline’s Zejula (niraparib) in final guidance. Zejula competes with AstraZeneca/Merck & Co’s PARP inhibitor class rival Lynparza (olaparib) but in this case it has an advantage in this maintenance therapy use as it can be used regardless of whether the BRCA mutation is present.
Pharma Times
JANUARY 13, 2021
First patient in global trial dosed in the UK
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
JANUARY 13, 2021
Fight the Fakes gathers manufacturers and other stakeholders to brainstorm on ways to combat falsified medicines and safeguard the worldâs medicine supply.
Drug Patent Watch
JANUARY 15, 2021
Annual Drug Patent Expirations for SYMDEKO+%28COPACKAGED%29 Symdeko (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. There are twenty patents protecting this drug. This…. The post New patent for Vertex Pharms drug SYMDEKO (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 13, 2021
Everything, from exercise classes to pub quizzes, went online last year – and medical education was no exception. In their droves, congresses, conferences, and masterclasses went virtual in a bid to ensure healthcare professionals were supported, up to date, and socially distanced. But is this change here to stay? Are the days of queuing for coffee, rushing to symposiums, and the glitzy conference dinner a thing of the past?
Pharma Times
JANUARY 14, 2021
Qualified pharmacists will administer the Pfizer/BioNTech vaccine at an in-store pharmacy
Outsourcing Pharma
JANUARY 11, 2021
The drug delivery platform company is exploring the viability of remdesivir and other potential treatments for the virus using its DehydraTECH technology.
Pharma Mirror
JANUARY 15, 2021
Whenever you see physicians, nurses, or any hospital worker, there’s a good chance that they’re wearing scrubs. This sanitary clothing or uniform was originally designed for use by surgeons and their support staff while in surgery rooms. It came to be known as scrubs because surgeons typically put them on as they sterilize or scrub themselves clean before entering the operating room.
pharmaphorum
JANUARY 15, 2021
South Korea’s Celltrion has announced encouraging top-line results for its potential antibody therapy for COVID-19, with the first part of a phase 2/3 trial showing it could cut recovery times and chances of progression from moderate to more severe disease. Several other companies are also working on antibody therapies and Eli Lilly’s bamlanivimab gained an FDA Emergency Use Authorization in November last year, shortly after Regeneron’s cocktail of casirivimab and imdevimab.
Pharma Times
JANUARY 15, 2021
Ensinfentrine is a first-in-class inhaled inhibitor of the enzymes phosphodiesterase 3 and 4
Outsourcing Pharma
JANUARY 13, 2021
The pharmaceutical firm reports a counterfeit version of its Symtuza HIV treatment has been found and pulled from shelves at three American pharmacies.
Drug Patent Watch
JANUARY 15, 2021
Annual Drug Patent Expirations for XPOVIO Xpovio is a drug marketed by Karyopharm Theraps and is included in one NDA. There are five patents protecting this drug. This drug has…. The post New patent for Karyopharm Theraps drug XPOVIO appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 13, 2021
IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) to further develop its cancer vaccine technology that has boosted efficacy of PD-1 immunotherapy in early trials. The Series B fundraiser follows the FDA’s decision to grant Breakthrough Therapy designation last month for a combination of its lead immune-oncology therapies IO102 and IO103, with anti-PD-1 monoclonal antibodies for patients with metastatic melanoma.
Pharma Times
JANUARY 12, 2021
CCS1477 has a novel mechanism of action compared to existing treatments
Outsourcing Pharma
JANUARY 12, 2021
A Miami physician has owned up to falsifying research data and patient participation figures for a pediatric asthma trial conducted from 2013 to 2016.
Drug Patent Watch
JANUARY 15, 2021
Annual Drug Patent Expirations for ICLUSIG Iclusig is a drug marketed by Ariad and is included in one NDA. There are three patents protecting this drug. This drug has seventy-eight…. The post New patent for ARIAD drug ICLUSIG appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 12, 2021
US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who have also signed separate partnerships to develop new therapies for neurological diseases using RNA interference (RNAi) technology. While there are RNAi products on the marketplace, with Alnylam becoming the first company to get a product approved in 2018, it is difficult to get this class of drug distributed through the brain and spinal cord.
Pharma Times
JANUARY 13, 2021
Investigational antibody targets a modified form of beta amyloid called N3pG
Outsourcing Pharma
JANUARY 12, 2021
Sosei Heptares and PharmEnable will harness artificial intelligence-enabled technology and advanced chemistry to explore neurological disease solutions.
Drug Patent Watch
JANUARY 15, 2021
Annual Drug Patent Expirations for KYNMOBI Kynmobi is a drug marketed by Sunovion Pharms Inc and is included in one NDA. There are fourteen patents protecting this drug. Drug patent…. The post New patent for Sunovion Pharms drug KYNMOBI appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 11, 2021
2020 was the year that changed everything, and as the new year begins many are wondering what awaits the world in 2021. Impetus Digital co-founder and CEO Natalie Yeadon reflects on the last 12 months and shares her views on the healthcare, research and digital changes that could be here to stay. I think it is fair to say that 2020 will not be particularly missed by anyone.
Pharma Times
JANUARY 13, 2021
MHRA submission is based on same application filed with the EMA
Outsourcing Pharma
JANUARY 13, 2021
Authorities discovered the fake Pfizer erectile-dysfunction tablets in one of three cargo containers full of fraudulent goods, recently arrived from China.
Drug Patent Watch
JANUARY 15, 2021
Annual Drug Patent Expirations for TRIKAFTA+%28COPACKAGED%29 Trikafta (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. There are twenty-one patents protecting this drug. This…. The post New patent for Vertex Pharms drug TRIKAFTA (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 14, 2021
When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a rare win for the amyloid hypothesis, although there’s no shortage of candidates that have failed despite positive mid-stage trial results. Some analysts have intimated that given the small size of the study at just over 270 patients, rival amyloid drug developers Biogen and Eisai could claim the biggest benefit from the data in positive sentiment ahead of an FDA decision later this year.
Pharma Times
JANUARY 15, 2021
In a Phase IIb trial, more patients experienced complete resolution of hives with ligelizumab compared to Xolair
Outsourcing Pharma
JANUARY 12, 2021
Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO.
Expert insights. Personalized for you.
119 
Let's personalize your content